Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality
AbstractTreatment modalities for desmoid tumors have been changed because of the high recurrence rate, even after wide resection, and some cases experience spontaneous self-regression during clinical course. The treatment modality in our institutions before 2003 was surgical resection with wide surgical margin, however, meloxicam, which is a NSAID and a selective COX-2 inhibitor has been applied consecutively since 2003. We reviewed the previously reported outcomes of surgical and conservative treatment in our institutions. Among 30 patients receiving surgical treatment, 16 (53%) recurred. Younger age ( p < 0.05) was a significant poor factor. According to RECIST for meloxicam treatment, CR was in one, PR in 10, SD in eight, PD in one evaluated at 2011. Older age ( p < 0.01) was significantly associated with good outcome for meloxicam treatment. Results of the previous study indicated that surgical treatment alone could not control desmoid tumors, even with negative surgical margin. Considering the functional impairment resulting from surgery with negative surgical margin, a conservative and effective treatment modality with fewer complications is desired. Conservative treatment with meloxicam is a promising novel modality for patients with extra-abdominal desmoid tumors. View Full-Text
Share & Cite This Article
Nishida, Y.; Tsukushi, S.; Shido, Y.; Urakawa, H.; Arai, E.; Ishiguro, N. Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality. Cancers 2012, 4, 88-99.
Nishida Y, Tsukushi S, Shido Y, Urakawa H, Arai E, Ishiguro N. Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality. Cancers. 2012; 4(1):88-99.Chicago/Turabian Style
Nishida, Yoshihiro; Tsukushi, Satoshi; Shido, Yoji; Urakawa, Hiroshi; Arai, Eisuke; Ishiguro, Naoki. 2012. "Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality." Cancers 4, no. 1: 88-99.